Freezing of Gait Treatment Market
Freezing of gait, or FOG, is said to affect approximately 7% of individuals with early Parkinson� ... Read More
Alpha thalassemia causes due to deficiency or absence of alpha globin chains results in alpha thalassemia which is asymptomatic with general hematologic findings and gains silent carrier status.
This report contains market size and forecasts of Alpha Thalassemia Treatment in Global, including the following market information:
Global Alpha Thalassemia Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Alpha Thalassemia Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Folic Acid Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Alpha Thalassemia Treatment include GlaxoSmithKline, Novartis AG, Bellicum Pharmaceuticals, Acceleron Pharma, Johnson & Johnson, Merck & Co. and Gilead Sciences, Inc., etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Alpha Thalassemia Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Alpha Thalassemia Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Alpha Thalassemia Treatment Market Segment Percentages, by Type, 2021 (%)
Folic Acid
Deferasirox
Deferiprone
Hydroxyurea
Global Alpha Thalassemia Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Alpha Thalassemia Treatment Market Segment Percentages, by Application, 2021 (%)
Hospitals
Ambulatory Surgical Centers
Others
Global Alpha Thalassemia Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Alpha Thalassemia Treatment Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Alpha Thalassemia Treatment revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Alpha Thalassemia Treatment revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
GlaxoSmithKline
Novartis AG
Bellicum Pharmaceuticals
Acceleron Pharma
Johnson & Johnson
Merck & Co.
Gilead Sciences, Inc.
Freezing of gait, or FOG, is said to affect approximately 7% of individuals with early Parkinson� ... Read More
EPrison solutions help administrators of correctional homes & prisons to get real-time access to ... Read More
Breastmilk substitute (BMS): any food being marketed or otherwise represented as a partial or tot ... Read More
Seismic retrofitting is the modification of existing structures to make them more resistant to se ... Read More